Acquiring Company
Nuvation Bio
Acquired Company
AnHeart Therapeutics
New YorkNew YorkBiotechnologyHealthcareHealth CareTherapeuticsBiopharmaManufacturingBiotechnologyHealth CareScience And EngineeringTherapeuticsPharmaceuticalBiopharmaDescription
Nuvation Bio Inc. (NYSE: NUVB) and AnHeart Therapeutics Ltd. have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction. This acquisition will strengthen Nuvation Bio's position as a late-stage global oncology company with a focus on delivering novel cancer therapies.
Quick answer
Nuvation Bio is acquiring AnHeart Therapeutics, announced March 25, 2024. Nuvation Bio is based in New York, New York, United States.
- How much did Nuvation Bio pay for AnHeart Therapeutics?
- The deal value was not disclosed.
- What does Nuvation Bio do?
- Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates.
- Where are Nuvation Bio and AnHeart Therapeutics based?
- Nuvation Bio is based in New York, New York, United States. AnHeart Therapeutics is based in New York, New York, United States.
- Who are the decision-makers at Nuvation Bio?
- Fundz holds 1 contact at Nuvation Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio (March 18, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Future Pak proposes acquisition of Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash (April 17, 2024)
- ONO completes acquisition of Deciphera Pharmaceuticals to reinforce its oncology portfolio (April 30, 2024)
Who to call at Nuvation Bio, and when
When Nuvation Bio changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Nuvation Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuvation Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuvation Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nuvation Bio makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired AnHeart Therapeutics?
AnHeart Therapeutics was acquired by Nuvation Bio, based in New York. The deal was reported on March 25, 2024. Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio is publicly traded (NUVB) and operates in Biotechnology.
When did Nuvation Bio acquire AnHeart Therapeutics?
Nuvation Bio's acquisition of AnHeart Therapeutics was reported on March 25, 2024. Nuvation Bio Inc. (NYSE: NUVB) and AnHeart Therapeutics Ltd. have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AnHeart Therapeutics do?
AnHeart Therapeutics Ltd. is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. It is privately held, operating in Manufacturing, and is based in New York.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.